Navigation Links
Telik Announces Publication of Positive Phase 1-2a Results of a Multicenter Study of TELCYTA(R) in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer
Date:10/1/2009

PALO ALTO, Calif., Oct. 1 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) today announced the publication of the positive results from a Phase 1-2a multicenter, dose-ranging study of TELCYTA in combination with carboplatin and paclitaxel as first-line therapy for patients with nonsmall cell lung cancer (NSCLC) in a leading peer reviewed publication, the Journal of Thoracic Oncology, October 2009; Vol. 4, No. 10. Data on this study were presented at the 98th annual meeting of the American Association for Cancer Research (AACR) on April 17, 2007.

One hundred twenty-nine patients were treated with TELCYTA in combination with carboplatin and paclitaxel, of whom 100 were continuing to respond at the end of combination therapy and eligible to receive single agent TELCYTA maintenance therapy. Those patients who received the TELCYTA combination therapy followed by TELCYTA maintenance therapy vs. no maintenance therapy had a median progression-free survival (PFS) of 6.8 months vs. 3.9 months, respectively (p< 0.0001). The difference in PFS correlated with a median survival of 16.8 months in the maintenance group vs. 8.8 months for those without maintenance therapy (p<0.0001). TELCYTA in combination with carboplatin and paclitaxel chemotherapy followed by TELCYTA maintenance therapy was well tolerated. TELCYTA may be suited to application as maintenance therapy, an area of current intense interest for the treatment of lung cancer patients. In addition, the regimen appeared active across all types of NSCLC and ongoing investigations are attempting to identify the characteristics of the NSCLC population most likely to benefit from this approach.

About Telik

Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to trea
'/>"/>

SOURCE Telik, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Telik Announces Presentation of Preclinical Data on Dual Inhibitors of Aurora Kinases and VEGFR2
2. Telik Announces Preclinical Data Demonstrating Anti-Cancer Activity of Dual Inhibitors of Aurora Kinase and VEGFR2
3. Telik Announces Telintra Presentation at American Society of Hematology Annual Meeting
4. Telik Announces Initiation of Two Phase 2 Randomized TELINTRA Studies
5. Teliks Proteasome Inhibitor Program Meets a Preclinical Development Milestone
6. Telik Announces Presentation at ASCO Annual Meeting
7. Telik Announces Publication of Positive Phase 1 Results of a Multicenter Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets In Patients With Myelodysplastic Syndrome
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)... SAN DIEGO, Nov. 25 NuVa...any focused on developing products for minimally d...nced today that it will host a conference call on ...p.m. PT. The conference call will focus on curren...,s products and will include comments from managem...
(Date:11/25/2009)...EW YORK, Nov. 25 Reportlinker.com ...ilable in its catalogue: ,, Intranasal Drug De...www.reportlinker.com/p0164267/Intranasal-Drug-Deli...US intranasal drug delivery market is witnessing a...elivery of conventional local therapeutic drugs to...
(Date:11/25/2009)... VIEW, Calif., Nov. 25 ChemoCent...cal data from the Company,s PROTECT-1 (the Prospec... disease Trial) of Traficet-EN(TM) (CCX282-B) in p...monstrated clinical efficacy with a favorable safe...ed evidence of clinical efficacy in the reduction ...
Breaking Medicine Technology:NuVasive Announces Conference Call and Webcast Regarding Reimbursement 2NuVasive Announces Conference Call and Webcast Regarding Reimbursement 3NuVasive Announces Conference Call and Webcast Regarding Reimbursement 4Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 2Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 4Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 5ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 6Dense Breasts Raise Risk of Cancer Recurrence 60997 1Dense Breasts Raise Risk of Cancer Recurrence 60997 2Dense Breasts Raise Risk of Cancer Recurrence 60997 3Mayo Researchers Find Robotic Repair for Vaginal Prolapse Has Significant Benefits 60994 1Mayo Researchers Find Robotic Repair for Vaginal Prolapse Has Significant Benefits 60994 2Mayo Researchers Find Robotic Repair for Vaginal Prolapse Has Significant Benefits 60994 3American Academy of Physician Assistants Applauds U S House of Representatives for Passing Health Care Reform Bill 60989 1American Academy of Physician Assistants Applauds U S House of Representatives for Passing Health Care Reform Bill 60989 2
... 09, 2007 /PRNewswire-FirstCall/ --,Telik, Inc. an...enter Phase 2 trial of the triplet combination of ... and paclitaxel will be,presented at the 98th annu...Research (AACR) in Los Angeles. Preclinical studie...tic cancer cell growth,inhibition with TELCYTA in ...
...SS WIRE)--Apr 11, 2007 - New data,supporting the c...,the most advanced investigational oral protease i...HCV) infection, will be presented,at the 42nd Annu...dy of the Liver (EASL) in Barcelona this week. In ...een accepted for presentation,at the EASL conferen...
Other Medicine Technology:Telik Announces Telcyta Clinical and Preclinical Presentations at,AACR Meeting 2Telik Announces Telcyta Clinical and Preclinical Presentations at,AACR Meeting 3Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 2Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 3Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 4Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 5Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 6
(Date:11/27/2009)..., Nov. 27 Preventing di...d fortunately every year, new vaccines are being a...accines boost immunity for the same period of time... needed to keep immunity strong? ,, In this m...rican Academy of Pediatrics, Michael Pichichero MD...
(Date:11/27/2009)...enaCare Holdings has announced that it has become ...e of the largest nonprofit organizations dedicated.... , Delray Beach, FL (Voc...OTCBB: XCHO), a company specializing in the market... products, has announced today that is has become ...
(Date:11/27/2009)... SEATTLE, Nov. 27 Allrecipes.com ... Thanksgiving traffic numbers, with more than 2.8 ...iding a clear picture of what was served on the bi...giving meal in 2009 weighed in at 2,225 calories p...feast. According to the Allrecipes site, Sweet Po...
(Date:11/27/2009)...pecialist manufacturers who use medical load cells...s of dollars by bringing in technology partner Fli...rs of pro-active medical manufacturers are calling... of their projects, ensuring that progress will no...otentially outdated technology. , ...
(Date:11/26/2009)...J., Nov. 27 The diabetes populatio... next 25 years and annual medical spending on the ...$113 billion today, according to a study published...tional Changing Diabetes ® Program (NCDP), a...s by a team from the University of Chicago. ,, ...
Breaking Medicine News(10 mins):Health News:Why Some Vaccines May Require A Booster 2Health News:Why Some Vaccines May Require A Booster 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 2Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 3Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 4Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 3Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 4
... of Delphon Industries and industry leader in Elec...today the appointment of Diablo Sales & Market...pport in the western United States and Western Can...terials used in injection molding and extrusion fo...
...ion for Homecare supports expanded anti-fraud effo...ice (DOJ) and the Department of Health and Human S...Medicare. The two agencies outlined plans for expa...e stepped-up DOJ-HHS effort, the American Associat...
...dition , , WEDNESDAY, May 20 (HealthDay Ne...sk of autism, particularly in boys, has been ident...f 1,046 members of families with at least two sons...ported. , This variant of the gene, which helps mo...
...y says , , WEDNESDAY, May 20 (HealthDay Ne...hospital with the intense chest pain that doctors ...r artery-opening procedures within a few hours, a ...is often an issue about whether such assessment an...
... when even teens who have never tried a drop of al... and graduation are big events and there will be m...rtunities for alcohol to be served. , Assume tha...or the Advancement of Science (AAAS). So start tal...
...hildren,s Pediatric Disorders , , SANTA MONICA, C... world leader in orthopaedic patient care, researc...day the Renee and Meyer Luskin Children,s Clinic o...world-class pediatric orthopaedic care. Renee and ...
Other Medicine News:Health News:TouchMark Announces New Sales Representative 2Health News:American Association for Homecare Supports Expanded Federal Efforts by DOJ and HHS to Combat Medicare Fraud 2Health News:American Association for Homecare Supports Expanded Federal Efforts by DOJ and HHS to Combat Medicare Fraud 3Health News:American Association for Homecare Supports Expanded Federal Efforts by DOJ and HHS to Combat Medicare Fraud 4Health News:Gene Gives Clues to Why Autism More Common in Boys 2Health News:When Chest Pain Requires Quick Action in ER 2Health News:When Chest Pain Requires Quick Action in ER 3Health News:Use science to convince teens a sober prom is better, AAAS says 2Health News:World-Class Pediatric Orthopaedic Clinic Now Open for Kids 2
ACE SCFE Screw
4.0 mm and 6.5 mm Cannulated Screws
...bles fixation of humeral shaft fractures while avo...associated with antegrade nailing. , ,In addition,...ng using a nail-mounted targeting device. This dev...th the patient in the prone position. In cases tha...
...edical technology company and a key participant in...es a new generation Automated Coagulation Timer. T...electromechanical coagulation instrument designed ... citrated whole blood, and plasma samples. Clottin...
Medicine Products: